PUBLICATION

CORRECTION: Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia

Authors
He, B.L., Yang, N., Man, C.H., Ng, N.K., Cher, C.Y., Leung, H.C., Kan, L.L., Cheng, B.Y., Lam, S.S., Wang, M.L., Zhang, C.X., Kwok, H., Cheng, G., Sharma, R., Ma, A.C., So, C.W.E., Kwong, Y.L., Leung, A.Y.
ID
ZDB-PUB-220906-212
Date
2020
Source
EMBO Molecular Medicine   12: e12911 (Other)
Registered Authors
Keywords
none
MeSH Terms
none
PubMed
32767634 Full text @ EMBO Mol. Med.
Abstract
Chi Wai Eric So's name had been spelled incorrectly. The spelling is herewith corrected.
Errata / Notes
This article corrects ZDB-PUB-200307-7.
Genes / Markers
Figures
No images available
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Citation
He, B.L., Yang, N., Man, C.H., Ng, N.K., Cher, C.Y., Leung, H.C., Kan, L.L., Cheng, B.Y., Lam, S.S., Wang, M.L., Zhang, C.X., Kwok, H., Cheng, G., Sharma, R., Ma, A.C., So, C.W.E., Kwong, Y.L., Leung, A.Y. (2020) CORRECTION: Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. EMBO Molecular Medicine. 12:e12911.